Westerhout, Cynthia M <br/><br/>
Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.  [electronic resource] 

 -  Expert opinion on drug safety  Jan 2003 
 - 49-58 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1474-0338 
<br/><br/><label>Standard No.: </label>10.1517/14740338.2.1.49  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Acetates--economics<br/>Acute Disease<br/>Antibodies, Monoclonal--economics<br/>Coronary Disease--drug therapy<br/>Drug Evaluation<br/>Eptifibatide<br/>Guidelines as Topic<br/>Humans<br/>Immunoglobulin Fab Fragments--economics<br/>Incidence<br/>Injections, Intravenous<br/>Peptides--economics<br/>Platelet Aggregation Inhibitors--economics<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Risk Assessment<br/>Tirofiban<br/>Treatment Outcome<br/>Tyrosine--analogs & derivatives